Recently, the non-steroidal mineralocorticoid receptor agonist finerenone, which had already been shown to reduce the risk of cardiorenal outcomes in patients with T2D, demonstrated a benefit on HF-related outcomes in patients with HFmrEF and HFpEF [11, 38]. The gene discussed is NR3C2; the disease is hydrops fetalis.